ARTICLE
Vol 134 No 1528: 15 January 2021
Prognostic significance of mid-range ejection fraction following acute coronary syndrome (ANZACS-QI 23)
Daniel Chan, Robert N Doughty, Mayanna Lund, Mildred Lee, Katrina Poppe, Andrew J Kerr
Reduced left ventricular ejection fraction (LVEF) is associated with adverse clinical outcomes after acute coronary syndrome (ACS), and clinical trials have established the role of beta-blockers, angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) and aldosterone antagonists in patients with LVEF<40% post-ACS.